Is it good or bad to find a BRAF mutation?

Journal of Clinical Oncology

Volumn 29, Issue 10, 2011, Pages 1229-1230

  Flaherty, Keith T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GSK 2118436; PLX 4032; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; EDITORIAL; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; THYROID CANCER; TUMOR SUPPRESSOR GENE;

AGE FACTORS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; MUTATION; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953844450     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0497     Document Type: Editorial

References (13)

1. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002 (Pubitemid 34716871)
2. Eisen T, Ahmad T, Flaherty KT, et al: Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis. Br J Cancer 95:581-586, 2006 (Pubitemid 44325897)
3. Flaherty KT, Kim KB, Ribas A, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
4. Kefford R, Arkenau H, Brown MP, et al: Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with meta-static melanoma and other solid tumors. J Clin Oncol 28:611s, 2010 (suppl; abstr 8503)
5. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
6. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
7. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
8. Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008 (Pubitemid 351264344)
9. Tsao H, Goel V, Wu H, et al: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337-341, 2004 (Pubitemid 38281053)
10. Long GV, Menzies AM, Nagrial AM, et al: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239-1246, 2011
11. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
12. Xing M, Westra WH, Tufano RP, et al: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379, 2005 (Pubitemid 41759286)
13. Oliveira C, Pinto M, Duval A, et al: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22:9192-9196, 2003 (Pubitemid 38067995)